If you read

This was posted a day or so ago:

About IP6 Cancer Adjuvant Therapy

Inositol hexaphosphate (IP-6)--activates natural killer cells, promotes differentiation, supports p53 activity, and normalizes the cell cycle by modifying signal transduction pathways
IP-6, a promising anticancer compound sold as a nutritional supplement, is a combination of inositol (a B vitamin) and phytic acid, also known as inositol hexaphosphate. According to Dr. A. Shamsuddin, M.D., Ph.D., who introduced IP-6 after more than 15 years of research, it works by enhancing the body's ability to defend itself against cancer, making it of equal importance as either a cancer preventive or therapeutic agent.

Inositol hexaphosphate is a sugar, very much like glucose, except it has six phosphates attached to its molecules. Every animal and plant species tested had varying levels of IP-6, but the highest amounts were found in rice, about 2% by weight: 100 grams of rice provide approximately 2 grams of IP-6, but even that amount is not readily available. Since the body is dependent upon digestive enzymes to break it down, only a meager amount is actually absorbed from foodstuffs. Thus, IP-6 in encapsulated or bulk forms should be of special interest to cancer patients and those desiring protection against cancer.

The following chemotherapeutic properties are assigned to the immune modulator:

IP-6 activates natural killer cells, amazing cells that work without antibody participation (Baten et al. 1989).
IP-6 decreases cellular proliferation (Sakamoto et al. 1993; Shamsuddin et al. 1989a). Normally, cells divide in a well-ordered fashion, with worn-out cells replaced with new, healthy cells. When regulatory control is lost, excess growth occurs and cancer can develop. Illustrative of its potential, IP-6 reduced large intestinal cancer (by regulating cell proliferation) in F344 rats even when the treatment was begun 5 months after carcinogenic induction (Shamsuddin et al. 1989b).
IP-6 promotes differentiation of cancer cells, that is, an unspecialized, atypical cell structure assumes the likeness of the tissue of origin, indicating the virulence of the malignancy is waning (Yang et al. 1995). IP-6 was shown to inhibit growth and induce differentiation in HT-29 human colon cancer cells, making it valuable as an adjunctive treatment in colon cancer. IP-6 also strongly inhibited growth and induced differentiation in human prostate cancer cells (PC-3) in both in vitro and in vivo studies (Shamsuddin et al. 1995).
Dr. A. Shamsuddin, research scientist and professor of pathology at the University of Maryland School of Medicine in Baltimore, explains that one of IP-6's cousins (IP-3, i.e., inositol with three phosphates) is a signal transduction molecule, meaning it relays messages to the cell. If the cell is exposed to a cancer-causing agent, a signal is transported from outside the cell into the cell (most probably to the nucleus) so the cell knows how to react to that particular stimulant. Since IP-3 is a "send" molecule and IP-6 is related to IP-3, but in a higher phosphorylated form, it is very possible that IP-6 could work against all varieties of cancer cells. To date, IP-6 has been effective against every cancer cell tested (Shamsuddin et al. 1997; Grases et al. 2002).
After inducing cancer in laboratory animals, IP-6 (administered orally, by injection at the site of the tumor, or intraperitoneally) resulted in tumors two-thirds smaller than the controls. As tumors reduced in size, survival rate increased (Shamsuddin et al. 1989b).
IP-6 increases expression of the tumor suppressor gene p53 by up to 17-fold. p53 acts on cells under stress, such as those with DNA damage, reducing proliferation and encouraging apoptosis. When cancer arises, a mutation in p53 is commonly involved. Lastly, since loss of p53 function increases cancer cells' resistance to chemotherapeutic agents, the stimulating action of IP-6 on p53 makes it an attractive adjuvant chemotherapeutic agent as well (Shamsuddin et al. 1997; Saied et al. 1998).
Toxicity studies (dating back to 1958) showed that a daily dose of 9 grams of IP-6 for 3 years resulted in only beneficial side effects, including lesser incidences of kidney stones and fatty liver, as well as lower cholesterol levels. It is important to note that IP-6 does not kill the cell, as most anticancer agents do; thus, hair loss and immune suppression does not occur. A suggested dosage of 1-3 grams a day is adequate for most individuals. For those requiring larger doses, a powder is available (1 scoop twice daily equals 16 capsules, supplying about 6.4 grams of Ip-6).

Recent studies show that as the intake of high fiber cereal diets increase, breast cancer rates fall. Inositol hexaphosphate (IP6) is abundant in cereals, legumes, and seeds. Experiments demonstrate a reproducible and striking anti-cancer action of IP6. It therefore appears that IP6 is one of the components, if not the most active ingredient, of high fiber cereal diet responsible for cancer inhibition. A study investigated a) whether dietary fiber containing high IP6 shows an inhibition of artificially induced breast cancer, and B) if pure IP6 is more active as a cancer preventive agent, compared to that in the diet. Results showed that supplemental dietary fiber in the form of bran exhibited a modest, statistically nonsignificant inhibitory effect. In contrast, animals given IP6 in drink showed significant reduction in tumor numbers. Therefore, pure IP6 is definitively more effective than a high fiber diet in preventing experimental mammary tumors. Thus, for cancer prevention, prophylactic intake of IP6 may be not only more effective, but also more practical than gorging on large quantities of fiber.